Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 45-year-old man comes to the clinic for a routine follow-up visit. Four weeks ago, he was diagnosed with active pulmonary tuberculosis and started on a daily regimen of isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine. The patient reports that his persistent cough and night sweats have significantly improved since starting therapy. He feels well and specifically denies any nausea, vomiting, abdominal pain, fatigue, or dark urine. Vital signs are within normal limits. Physical examination reveals no scleral icterus, and the abdomen is soft and non-tender without hepatomegaly. Routine follow-up laboratory studies are obtained and show the following results:

Laboratory TestResultReference Range
Aspartate aminotransferase (AST)155 U/L8-40 U/L
Alanine aminotransferase (ALT)215 U/L7-56 U/L
Total bilirubin0.9 mg/dL0.1-1.2 mg/dL
Alkaline phosphatase85 U/L44-147 U/L

Which of the following is the most appropriate next step in the management of this patient?

  1. Continue the current medication regimen and monitor liver chemistries closelyAnswer
  2. B
    Discontinue all antituberculous medications until transaminases normalize
  3. C
    Discontinue pyrazinamide and continue the remaining medications
  4. D
    Obtain a right upper quadrant abdominal ultrasound
  5. E
    Order a comprehensive acute viral hepatitis serology panel

Answer

Continue the current medication regimen and monitor liver chemistries closely
The correct answer is to continue the current medication regimen and monitor liver chemistries closely. Mild to moderate asymptomatic elevation of hepatic transaminases is a common side effect of first-line anti-tuberculosis therapy (particularly isoniazid, rifampin, and pyrazinamide). Current guidelines specify that hepatotoxic tuberculosis medications should be discontinued only if transaminases rise to greater than 3×3 \times the upper limit of normal (ULN) in the presence of symptoms (e.g., nausea, vomiting, abdominal pain, jaundice), or greater than 5×5 \times the ULN in the absence of symptoms. This patient's transaminases are elevated to approximately 3.9×3.9 \times the ULN, but he is completely asymptomatic. Therefore, the threshold for discontinuing therapy (>5×> 5 \times ULN) has not been met, and the appropriate management is to continue the life-saving regimen while closely monitoring his liver function.

Step-by-Step Solution

1
Analyze the patient's clinical symptoms.
The patient is completely asymptomatic, specifically denying nausea, vomiting, abdominal pain, fatigue, and jaundice.
The presence or absence of symptoms dictates the threshold for discontinuing hepatotoxic medications.
2
Evaluate the laboratory results against reference ranges.
AST is 155155 U/L (approximately 3.9×3.9 \times upper limit of normal) and ALT is 215215 U/L (approximately 3.8×3.8 \times upper limit of normal). Bilirubin and alkaline phosphatase are normal.
Calculating the exact multiple of the upper limit of normal (ULN) is required to apply drug-induced hepatotoxicity guidelines.
3
Apply hepatotoxicity guidelines for first-line anti-tuberculosis therapy.
Guidelines dictate discontinuing drugs if transaminases are >3×> 3 \times ULN with symptoms, OR >5×> 5 \times ULN without symptoms. This patient is asymptomatic and <5×< 5 \times ULN.
Mild to moderate asymptomatic transaminitis is an expected side effect that often resolves or stabilizes without intervention.
4
Formulate the management plan.
The most appropriate step is to continue the current therapy and monitor closely.
Premature cessation risks treatment failure, whereas continued monitoring safely manages the expected side effects.

Key Concept

Management of anti-tuberculosis drug-induced hepatotoxicity is dictated by symptom presence: stop therapy if transaminases are >3x ULN with symptoms, or >5x ULN without symptoms.
Estimated Time:1m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic